- Policy
- Pariet holder was changed from Janssen to Kolmar in 20 years
- by Lee, Tak-Sun Jul 6, 2020 06:15am
- The domestic license holder for 'Pariet', a PPI used for GERD, has been changed in 20 years. As Janssen Korea operates the Hyangnam factory until next year, the manufacturer has finally changed. Eisai Korea is in charge of sales. According to related industries on the 3rd, the permit holders of Pariet licensed in 2000 were changed fr
- Company
- GC Pharma has signed a contract to supply Pfizer's Rapamune
- by Jul 6, 2020 06:15am
- GC Pharma is launching a sale of Rapamune (Sirolimus), an immunosuppressive agent of Pfizer Korea. According to the distribution industry on the 3rd, GC Pharma signed a supply contract with Pfizer Korea for supply of Rapamune 0.5·1·2mg on the 19th of last month and began selling on the 1st of this month. Rapamune is an immunosuppressive
- Company
- Hanmi appealed patent lawsuit of Galvus
- by Kim, Jin-Gu Jul 6, 2020 06:14am
- As soon as the Patent Judge sidede with the original company in the patent dispute of Galvus (Vildagliptin), a DPP-4 inhibitor-based diabetes treatment agent, Hanmi immediately announced its appeal. An official from Hanmi said in a call with Dailypharm on the 2nd, "We will appeal immediately and receive a trial for the scope of the patent
- Company
- Hanmi loses first trial in patent dispute over Galvus
- by Kim, Jin-Gu Jul 6, 2020 06:14am
- Novartis won the patent dispute between Hanmi and Novartis over the DPP-4 inhibitor-based diabetes treatment agent Galvus (Vildagliptin). The Intellectual Property Trial And Appeal Board made a decision to dismiss the passive right scope verification trial requested by Hanmi on the 1st. Hanmi has filed a total of eight trials for Galvus p
- Policy
- Korean government designates remdesivir essential drug
- by Lee, Tak-Sun Jul 6, 2020 06:14am
- The Korean government has designated specially imported COVID-19 treatment remdesivir, and clinically used COVID-19 treatment Kaletra (lopinavir/ritonavir) as National Essential Drugs. National Essential Drugs are designated to be constantly monitored for stock and supply flow, and to receive support for special importation clearance or
- Company
- AML treatment Rydapt can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 3, 2020 06:18am
- Novartis' new acute myelogenous leukemia drug 'Rydapt' can be prescribed in general hospitals. According to the related industry, acute myeloid leukemia (AML) treatment, Rydapt (Midostaurin) has passed the pharmaceutical committee (DC, drug commitee) of Big 5 Hospitals, such as Seoul National University Hospital and AMC. It was approved
- Opinion
- [Reporter’sView] Finding the key in platform technology
- by An, Kyung-Jin Jul 3, 2020 06:18am
- The world is eyeing on companies developing platform technology for novel drug. In last few years, Korean bio technology companies like ABL Bio, LegoChem Biosciences and Alteogen have signed deals worth over a trillion won with global pharmaceutical companies on rights over platform technology that facilitates drug delivery. Each in last
- Policy
- 33 seriously ill patients are eligible for free Remdesivir
- by Kim, Jung-Ju Jul 3, 2020 06:18am
- Gilead Science Korea's COVID-19 treatment 'Remdesivir' was supplied to Korea on the 1st of today. A total of 33 seriously ill candidates will be eligible for the first free application. However, they request to be administered at the discretion of the attending physician, and whether or not to administer is determined according to the sel
- Policy
- It started supplying Remdesivir to Korea for free for July
- by Lee, Tak-Sun Jul 3, 2020 06:17am
- Gilead's 'Remdesivir', a COVID-19 treatment, is supplied to Korea. In the month of July, the supply will be used free of charge. It is planned to be purchased and used through price negotiations after August. The director of The KCDC (Jung Eun-Kyeong) announced that it will supply Remdesivir, which was specially imported as a treatment for
- Policy
- Lipiodol takes government’s pricing reduction to the court
- by Kim, Jung-Ju Jul 3, 2020 06:17am
- The government’s price reduction on Lipiodol Ultra Solution (iodized oil), supposed to be effective from July 1 with the release of generic, is now heading to the courts as the company objected to the decision. Until the judgment is made, the court has allowed Guerbet Korea to sell the drug for the original reimbursed price temporarily
